Baiji Shenzhou: Signs $885 Million Franchise Agreement.

BeiGene announces that the company has signed a purchase agreement with Royalty Pharma for the rights to use the Imdelltra franchise fee. According to the agreement, Royalty Pharma will pay BeOne Medicines I GmbH, a subsidiary of BeiGene, a down payment of $885 million upon delivery, to purchase the rights to use the franchise fee for the sale of the Imdelltra product outside of China. The agreement allows the seller to sell more rights to use the franchise fee before August 25, 2026, with a maximum additional payment of $65 million. The agreement includes customary representations, warranties, and indemnification clauses, with the down payment expected to constitute a significant direct financial obligation for the company.